13F Holdings
中文EN

CABA Cabaletta Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1759138 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-19.5%
TTM EPS YoY44.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-89.5%
ROA-72.0%
ROIC (approx.)-479.6%
Asset turnover—

Leverage & solvency

Liabilities / assets15.6%
Debt / equity0.00x
Current ratio6.55x
Interest coverage-87.26x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$142.67M$97.20M$55.42M$39.30M$32.49M
SG&A expense$29.57M$27.94M$19.24M$14.84M$13.82M
Operating income-$172.24M-$125.14M-$74.66M-$54.14M-$46.31M
Interest expense$2.00M$748,000$0——
Income tax$0$0———
Net income-$167.86M-$115.86M-$67.67M-$52.98M-$46.29M
EBITDA-$170.59M-$123.43M-$73.23M-$52.96M-$45.58M
EPS (basic)-2.10-2.34-1.65-1.81-1.80
EPS (diluted)-2.10-2.34-1.65-1.81-1.80
Balance sheet
Cash & equivalents$82.98M$163.96M$193.24M$81.61M$122.22M
Short-term investments$50.62M$0$48.01M$24.94M$0
Current assets$138.87M$166.68M$244.49M$108.83M$124.54M
PP&E, net$1.92M$2.74M$2.54M$2.58M$1.44M
Total assets$165.08M$185.05M$253.65M$116.97M$126.34M
Current liabilities$50.15M$27.09M$15.99M$9.49M$8.38M
Total liabilities$53.03M$32.71M$17.45M$12.45M$8.38M
Shareholders' equity$112.05M$152.34M$236.20M$104.52M$117.96M
Shares outstanding100.48M50.74M47.82M29.45M28.93M
Cash flow statement
Operating cash flow-$131.08M-$88.22M-$53.55M-$46.38M-$34.11M
Capital expenditure$1.23M$2.21M$687,000$2.45M$1.17M
Free cash flow-$132.31M-$90.43M-$54.24M-$48.83M-$35.27M
Investing cash flow-$50.27M$47.29M-$22.45M-$27.22M$6.00M
Financing cash flow$100.35M$11.68M$187.63M$32.98M$48.90M
Depreciation & amortization$1.65M$1.71M$1.43M$1.18M$733,000
Stock-based compensation$20.94M$19.46M$11.34M$6.90M$5.80M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.